PMN ProMIS: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

This daily price chart for ProMIS Neurosciences (PMN) reflects an EV/EBITDA ratio of 0.00. ProMIS Neurosciences develops specific antibodies to combat dementia, generating sustainable solvent demand over the long term. Its high-tech production is based on a selective approach to neuron therapy. Authoritative management ensures the success of the business model by effectively advancing innovative developments through the stages of clinical trials.

Scaling the expansion of PMN310 antibodies requires significant capital expenditures; therefore, the EV/EBITDA multiple history of the business allows for an objective valuation of ProMIS Neurosciences (PMN) assets, accounting for the debt load. This indicator compares total market capitalization and loans against operating profit before taxes, helping investors identify excessive leverage risks and determine the issuer's financial stability.